Released Mar 26, 2026, before the open
10-K filed Mar 26, 2026, 85 days after period end · 0001628280-26-021413
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$25.14M-$25.14M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$25,199,000N/M
Operating Cash Flowderived-$19,096,000N/M
Free Cash Flowderived-$19,096,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$25.14M | -$37.15M | -$16.50M | -$12.87M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR